Tuberculosis Clinical Trial
— CHIP-TBOfficial title:
Community Initiated Preventive Therapy for TB (CHIP-TB Trial)
Verified date | August 2023 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: The World Health Organization (WHO) currently recommends household contact investigation for new tuberculosis (TB) patients in low- and middle-income countries, with an emphasis on pediatric contacts. Although the aim of this policy is to find previously undetected TB patients and reduce transmission, such investigations represent a missed opportunity to start contacts without TB on preventive therapy (TPT). The WHO guidelines do not address the optimal implementation of contact investigation. The standard of care (SOC) in most settings, passive referral of pediatric contacts to the clinic by the index TB patient, has largely remained unsuccessful in practice. In 2017, the WHO estimated only 23% of eligible child contacts were started on TB preventive therapy. Household contact investigation has been shown to have a higher yield in active TB case finding, but is labor intensive, and may be challenging to implement in densely populated urban settings or informal settlements/slums. The WHO recently endorsed the use of a new TPT regimen (rifapentine and isoniazid weekly (3HP)) for both children and adults in high burden settings, and the programmatic roll out of this regimen offers the opportunity to simultaneously examine new strategies to improve the identification and treatment of pediatric TB household contacts. Objective: To compare the effectiveness of community-based versus facility-based child contact investigation and delivery of TB preventive care to inform the optimal implementation strategy for investigating pediatric household TB contacts. Study Design: Cluster-randomized trial in 32 clinics (16 clinics per arm) divided equally among South Africa and Ethiopia (8 clinics per arm per country). Methods: Newly diagnosed qualifying TB index patients (determined by South African or Ethiopian National TB guidelines) and participants' household child contacts will be recruited to participate. Local staff, including the relevant nurses and community health workers in the intervention and control clinics, will be trained to conduct contact investigation with a symptom-based approach for all child contacts under 15 years old in home and at the clinic. Data will be collected using routine medical files and then retrospectively abstracted by the research team. Thirty-two primary health clinics will be stratified (by TB case notification and by country) and randomized in 1:1 fashion to either community-based or facility-based delivery of care. Household child contacts under 15 years of age who screen negative for TB disease will be initiated on TPT by a healthcare worker (nurse, community health worker, etc.) either in the home or clinic setting. Children in the intervention arm who screen positive will first be sent to the nurse at the clinic for repeat screening. Children who have a persistently positive screen in the intervention arm and those with a positive screen in the control arm using South Africa's or Ethiopia's pediatric symptom screening tool will be referred to a physician at the district hospital for further investigation of TB disease, as is the standard of care in both settings. Investigators will compare clinic-level outcomes including proportion of household TB contacts under 15 years of age that were screened, initiated on TPT, and who completed TPT, and reasons for not completing TPT including loss to follow up and incident TB disease while on TPT.
Status | Completed |
Enrollment | 1168 |
Est. completion date | June 30, 2023 |
Est. primary completion date | March 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 0 Days to 14 Years |
Eligibility | Inclusion Criteria: Inclusion Criteria for Index Patient in South Africa: - Adult pulmonary TB patient being treated for pulmonary TB disease (with bacteriologic confirmation including smear, GeneXpert® MTB/RIF and/or liquid mycobacterial culture) in one of the participating clinics - Willing to have a home visit and disclose their diagnosis to household members - Lives in the catchment areas of a study clinic - Age 18 years or older - Provides informed consent Inclusion Criteria for Index Patient in Ethiopia: - Adult or child being treated for pulmonary TB disease (clinical with or without microbiologic diagnosis) in one of the participating clinics - Willing to have a home visit and disclose their diagnosis to household members - Lives in the catchment areas of a study clinic - Age 18 years or older - Provides informed consent Inclusion Criteria for Contact in South Africa: - Child less than 15 years old living in the household of the TB index patient - Caregiver willing to provide informed consent - Children 7 years and older must also provide assent Inclusion Criteria for Contact in Ethiopia: - Child less than 15 years old living in the household of the TB index patient - Caregiver willing to provide informed consent - Children 12 years and older must also provide assent Exclusion Criteria: Exclusion Criteria for Index Patient in South Africa and Ethiopia: - Extrapulmonary TB with no evidence of concurrent pulmonary TB - Evidence of rifampin and/or isoniazid resistance on GeneXpert® MTB/RIF or drug sensitivity testing performed on M. tuberculosis isolates identified on culture - Household has already participated in study (more than one index patient in the household) and child contacts under 15 years have already been evaluated and remain on TPT and/or TB treatment Exclusion Criteria for Contact in South Africa: - Household child contact of a drug-resistant TB index patient. (Drug resistance defined either by the presence of rifampin resistance on GeneXpert® MTB/RIF OR drug sensitivity testing on isolates identified by culture). Exclusion Criteria for Contact in Ethiopia: - Household child contact of a drug-resistant TB index patient. (Drug resistance defined either by the presence of rifampin resistance on GeneXpert® MTB/RIF OR drug sensitivity testing on isolates identified by culture). - Household contact 15 years and older |
Country | Name | City | State |
---|---|---|---|
Ethiopia | KNCV-Ethiopia | Oromia Region | Oromia |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | Aurum Institute, KNCV Tuberculosis Foundation, UNITAID |
Ethiopia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The cluster-level ratio of the number of household child contacts less than 15 years of age initiated on TB preventive therapy (TPT) per index patient, comparing the intervention to the control arm | TPT includes 3 months of weekly rifapentine and isoniazid, 3 months of daily rifampin and isoniazid or 6 months of isoniazid | 4 months | |
Secondary | The cluster-level ratio of the number of household child contacts less than 15 years of age identified per index patient, comparing the intervention to the control arm | 4 months | ||
Secondary | The cluster-level proportions of estimated child contacts under 15 years who are identified | We will calculate the estimated child contacts per household using Demographic and Health Survey data and prior community-based contact tracing studies in both South Africa and Ethiopia. We will measure identified child TB contacts using the index patient's clinic-based contact tracing report, the child contact management file and the community-level file maintained by community health teams. | 6 months | |
Secondary | The cluster-level proportions of estimated child contacts under 15 years who are screened | We will calculate the estimated child contacts per household using Demographic and Health Survey data and prior community-based contact tracing studies in both South Africa and Ethiopia. We will define screening as the child's documented visit to the TB clinic or a documented visit to the home by the community health team (where the child was present) within four months of the index patient's TB clinic admission. | 6 months | |
Secondary | The cluster-level proportions of estimated child contacts under 15 years who are initiated on TB preventive therapy | We will calculate the estimated child contacts per household using Demographic and Health Survey data and prior community-based contact tracing studies in both South Africa and Ethiopia. Clinic staff or community health workers will document TPT initiation on the child contact management file. | 6 months | |
Secondary | The cluster-level proportions of estimated child contacts under 15 years who complete TB preventive therapy | We will calculate the estimated child contacts per household using Demographic and Health Survey data and prior community-based contact tracing studies in both South Africa and Ethiopia. Clinic staff or community health workers will document TPT completion on the child contact management file. | 6 months | |
Secondary | The cluster-level ratio of the number of household child contacts less than 15 years of age initiated on TB preventive therapy per index patient, comparing the intervention to the control arm in South Africa | 4 months | ||
Secondary | The cluster-level ratio of the number of household child contacts less than 15 years of age initiated on TB preventive therapy per index patient, comparing the intervention to the control arm in Ethiopia | 4 months | ||
Secondary | The cluster-level ratio of the number of household child contacts less than 15 years of age initiated on TB preventive therapy per index patient, comparing the intervention to the control arm among those less than 5 years of age | 4 months | ||
Secondary | The proportion of child contacts, by study arm, who discontinued TPT due to incident TB | 6 months | ||
Secondary | The proportion of child contacts, by study arm, who discontinued TPT due to pregnancy | 6 months | ||
Secondary | The proportion of child contacts, by study arm, who discontinued TPT due to severe malaria | 6 months | ||
Secondary | The proportion of child contacts, by study arm, who discontinued TPT due to a side effect | 6 months | ||
Secondary | The proportion of child contacts, by study arm, who were lost to follow up | 6 months | ||
Secondary | The proportion of children, by study arm, who were HIV-tested | 3 months | ||
Secondary | The proportion of newly diagnosed HIV-positive children, by study arm, who are referred for initiation of antiretroviral therapy by the community health team | 3 months | ||
Secondary | The proportion of newly diagnosed HIV-positive children, by study arm, who are initiated on antiretroviral therapy | 3 months | ||
Secondary | The proportion of identified child contacts in the intervention arm whose caregiver agrees for them to be screened by community-based healthcare workers in their home | 4 months | ||
Secondary | Mean number of attempted household visits per household | 6 months | ||
Secondary | Mean duration of time per household visit | 6 months | ||
Secondary | The proportion of TB contacts initiated on the correct TPT regimen by age and HIV status | 6 months | ||
Secondary | The proportion of TPT initiations with the correct dose for weight | 6 months | ||
Secondary | Proportion of TB index patient households in the intervention arm who refused a household visit due to stigma | 6 months | ||
Secondary | Proportion of TB index patient households in the intervention arm who refused a household visit due to lack of time | 6 months | ||
Secondary | Proportion of TB index patient households in the intervention arm who refused a household visit due to well status of the child | 6 months | ||
Secondary | Proportion of TB index patient households in the intervention arm who do not receive a home visit because the family and/or child was not home on three separate attempts | 6 months | ||
Secondary | Proportion of TB index patient households in the intervention arm who refused a household visit due to fear of disclosure | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 | |
Recruiting |
NCT02807025 -
Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases
|
N/A |